VYNE Therapeutics Inc. (NASDAQ: VYNE) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT VYNE THERAPEUTICS INC.

VYNE Therapeutics Inc. (NASDAQ: VYNE)
Listen to this Section


$0.66
-0.0140 ( -2.07% ) 92.8K

VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.

Clinical Trial Pipeline Stages


Drug Name Stage
Zilxi (Minocycline)DetailsRosacea Approved
Amzeeq (minocycline)DetailsAcne vulgaris Approved
VYN201DetailsVitiligo Phase 2b
VYN202DetailsPsoriasis, Rheumatoid arthritis Phase 1a
FMX114 (tofacitinib and fingolimod)DetailsAtopic dermatitis Failed
FCD105 (minocycline & adapalene)DetailsAcne vulgaris Failed

Market Data


Open $0.66
Previous Close $0.68
Volume 92.8K
Market Cap $22.55M
Day Range $0.65 - $0.68
52 Week Range $0.28 - $1.96
Shares Outstanding 33.35M
Change % -2.07%
Net Change ▼ -0.0140
Insider Ownership -0.01%
Exchange NASDAQ
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2018
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -1,058,411.00

Date Type Amount Purchased Purchaser
2025-01-16 Buy 15000.00 LEPORE PATRICK G
2024-07-03 Sale -935.00 Domzalski David
2024-07-03 Sale -92.00 Zeronda Tyler
2024-07-03 Sale -138.00 Stuart Iain
2024-07-03 Sale -143.00 Harsch Mutya
2024-06-04 Sale -4429.00 Domzalski David
2024-04-03 Sale -157.00 Stuart Iain
2024-04-03 Sale -161.00 Harsch Mutya
2024-04-03 Sale -1004.00 Domzalski David
2024-04-03 Sale -94.00 Zeronda Tyler

SEC Filings


Form Type Description Pages Date
def Proxies and info statements 21 Nov 12, 2025
ars Annual reports 1 Nov 12, 2025
8-k 8K-related 14 Nov 06, 2025
10-q Quarterly Reports 6 Nov 06, 2025
4 Insider transactions 1 Oct 02, 2025
4 Insider transactions 1 Oct 02, 2025
4 Insider transactions 1 Oct 02, 2025
4 Insider transactions 1 Oct 02, 2025
8-k 8K-related 12 Sep 12, 2025
10-q Quarterly Reports 63 Aug 14, 2025

Latest News


× Before browsing our site, please accept our cookies policy